NICE recommendation for AbbVie’s Rinvoq
The approved drug has been developed to treat patients with moderate to severe Crohn’s disease
Read More
Tag: Rinvoq
Green light for AbbVie’s Crohn’s disease therapy Rinvoq
MHRA approval for Rinvoq which treats adults with moderate to severely active Crohn’s Disease
Read More
Scottish Medicines Consortium agrees to use of Rinvoq
Therapy will now treat adults across Scotland with moderate rheumatoid arthritis
Read More
AbbVie’s Rinvoq gains recommended approval by CHMP
CHMP returns positive opinion on Rinvoq for the treatment of adults with active non-radiographic axial spondyloarthritis
Read More
NICE backs Rinvoq for moderate active RA
Decision expands access to oral therapy to around 27,000 people in England
Read More
MHRA nod for AbbVie’s Rinvoq for adults and adolescents with eczema
Large-scale phase III study met all primary and secondary endpoints
Read More
EU approval for Rinvoq to treat atopic dermatitis
Positive Phase III results for Abbvie’s oral JAK inhibitor
Read More
Rinvoq scores positive results as a maintenance therapy for ulcerative colitis
JAK inhibitor hit primary endpoint of improved clinical remission at 52 weeks in maintenance study
Read More
SMC approves funding for four new medicines on the NHS
BMS’ MS therapy Zeposia and AbbVie’s JAK inhibitor Rinvoq among latest approvals
Read More
AbbVie’s Rinvoq bags two new EU approvals
Oral JAK inhibitor approved for psoriatic arthritis and ankylosing spondylitis
Read More
NICE backs AbbVie’s Rinvoq for severe active rheumatoid arthritis
Around 400,000 people in the UK are living with rheumatoid arthritis
Read More
AbbVie submits Rinvoq for ankylosing spondylitis
In a pivotal Phase II/III study, twice as many patients receiving the drug achieved the primary endpoint of ASAS 40 response at week 14 versus placebo
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
